Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Clin Cancer Res. 2019 Jun 21;25(19):5984–5996. doi: 10.1158/1078-0432.CCR-18-3399

Figure 6. FGTI-2734 inhibits the viability, in 2-dimension, 3-dimension, and 3-dimension co-cultures with pancreatic stellate cells (PSCs) of low-passage primary and metastatic mutant KRAS adenocarcinoma cells derived from pancreatic cancer patients.

Figure 6.

Cells derived from patients 107, 108, 50, 43 and 69 (please see Table 1 for more detail) were cultured as described in Methods and subsequently treated for 72 hours with indicated concentrations of FGTI-2734. A, B, C cells were derived from patient # 43. A, Live-cell imaging was carried out with the IncuCyte Zoom at 72 hours (representative image). B, Cell number was analyzed using IncuCyte software on day 0 and 72 hour posttreatment; day 0 was used as control. C, Cell viability was determined using the CellTiter-Glo luminescent cell viability assay (representative image). D, IC50 was determined for pancreatic cancer cells (derived from 5 patients) treated for 72 hours with FGTI-2734 using GraphPad Prism 7.02 software.